(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 August 2013 (08.08.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/116325 A1

(51) International Patent Classification:
A61K 31/198 (2006.01) *A61P 25/14* (2006.01)

(21) International Application Number:
PCT/US2013/023828

(22) International Filing Date:
30 January 2013 (30.01.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/592,755 31 January 2012 (31.01.2012) US

(71) Applicant: **CHELSEA THERAPEUTICS, INC.** [US/US]; 3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277 (US).

(72) Inventors: **HEWITT, Arthur L.**; 8031 Pemswood Street, Charlotte, North Carolina 28277 (US). **SCHWIETERMAN, William**; 3901 Point Road, Mobile, Alabama 36619 (US). **SZAKACS, Cameron**; 10311 Gunnison Lane, Charlotte, North Carolina 28277 (US). **ROWSE, Gerry**; 111 Abbotsbury Court, Waxhaw, North Carolina 28173 (US). **CIOFFI, Christopher**; 360 Viburnum Way Court, Charlotte, North Carolina 28208 (US). **ROBERTS, Michael J.**; 7805 Pemswood Street, Charlotte, North Carolina 28277 (US).

(74) Agent: **CAGLE, Ryan W.**; Womble Carlyle Sandridge & Rice, LLP, P.O. Box 7037, Atlanta, Georgia 30357-0037 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

WO 2013/116325 A1

(54) Title: IMPROVING POSTURAL STABILITY ADMINISTERING DROXIDOPA

(57) Abstract: The present invention provides methods and systems for reducing falls in patients that are recurrent fallers. Specifically, the compositions, systems, and methods can relate to Parkinson's disease patients, particularly such patients that are suffering from neurogenic orthostatic hypotension. The compositions, systems, and methods comprise the use of droxidopa, optionally in combination with a further active agent. Administration of droxidopa has been found to reduce the mean number of falls per patient per week, as well as provide improvements in the patient's Hoehn and Yahr rating scale score, which is indicative of improvements in postural stability, and provide improvements in the patient's Unified Parkinson's disease Rating Scale score, which is indicative of improvements in the severity of motor and/or non-motor symptoms of Parkinson's disease.